TCGA-D6-6827-01A-11R-1915-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.230
- MYC_TARGETS_V2+0.190
- WNT_BETA_CATENIN_SIGNALING+0.160
- NOTCH_SIGNALING+0.110
- DNA_REPAIR+0.080
- SPERMATOGENESIS+0.080
- E2F_TARGETS+0.070
- MYC_TARGETS_V1+0.040
- BILE_ACID_METABOLISM+0.020
- KRAS_SIGNALING_DN+0.020
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.550
- TNFA_SIGNALING_VIA_NFKB-0.510
- CHOLESTEROL_HOMEOSTASIS-0.480
- INFLAMMATORY_RESPONSE-0.470
- MTORC1_SIGNALING-0.470
- IL6_JAK_STAT3_SIGNALING-0.460
- APOPTOSIS-0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- ALLOGRAFT_REJECTION-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_BA6AZWB3 | medulloblastoma | — | 0.925 |
| 2 | SRR934905 | — | — | 0.917 |
| 3 | BS_4W68NV3M | medulloblastoma | — | 0.915 |
| 4 | SRR650166 | — | — | 0.914 |
| 5 | BS_QRDT19KS | medulloblastoma | — | 0.913 |
| 6 | BS_PQVTB6BB | high-grade glioma | — | 0.911 |
| 7 | SRR8518450 | — | A | 0.909 |
| 8 | SRR934771 | — | — | 0.909 |
| 9 | TCGA-FJ-A3ZF-01A-11R-A23N-07 | — | — | 0.900 |
| 10 | SRR8518343 | — | E | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.190 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.070 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.040 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |